Trials / Completed
CompletedNCT03326973
Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 107 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To identify and describe long-term quality of life (QOL) issues in patients with metastatic melanoma treated with checkpoint inhibitors who achieved cancer control for a minimum of 12 months and remain on maintenance checkpoint inhibitor therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | EuroQoL EQ-5D-3L | Overall QOL |
| BEHAVIORAL | EORTC QLQ-C30 | General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales |
| OTHER | PRO-CTCAE | Additional potential immune-specific symptoms |
| BEHAVIORAL | Fatigue severity score questionnaire | Fatigue severity |
| BEHAVIORAL | The COST | Financial toxicity; satisfaction with ability to work |
| BEHAVIORAL | Physician information | Details on outside health providers |
Timeline
- Start date
- 2017-10-25
- Primary completion
- 2020-12-14
- Completion
- 2020-12-14
- First posted
- 2017-10-31
- Last updated
- 2020-12-17
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03326973. Inclusion in this directory is not an endorsement.